Sign in
8-K

Current Report

Tempest Therapeutics, Inc. Filed Acc 0001104659-16-163789

Exit or restructuring costs · Executive or director change · Bylaws or fiscal year change

  • Item 2.05 Costs associated with exit or disposal activities
  • Item 5.02 Departure or appointment of directors or officers
  • Item 5.03 Amendments to articles or bylaws; change in fiscal year

From the SEC's structured data for this filing

Loading a16-23647_18k.htm…